Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 7/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 2/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8221812 | 1.00 | CHRM4 (0.38) | CHRM4HPGDSRETADAM17RPS6KB1 | |
| SCHEMBL8274740 | 0.90 | HPGDS (0.36) | HPGDSRPS6KB1DGAT2 | |
| SCHEMBL8217550 | 0.88 | ADAM17 (0.44) | CHRM4HPGDSRETADAM17RPS6KB1 | |
| SCHEMBL14452920 | 0.86 | CHRM4 (0.41) | CHRM4RETADAM17NAMPTGPR6 | |
| SCHEMBL8221551 | 0.86 | CHRM4 (0.41) | CHRM4RETADAM17NAMPTGPR6 | |
| SCHEMBL14452921 | 0.82 | CHRM4 (0.47) | CHRM4RETADAM17RPS6KB1CHRNA7 | |
| SCHEMBL8221818 | 0.82 | CHRM4 (0.47) | CHRM4RETADAM17RPS6KB1CHRNA7 | |
| SCHEMBL14452911 | 0.79 | CHRM4 (0.38) | CHRM4RETADAM17RPS6KB1CHRNA7 | |
| SCHEMBL8223297 | 0.79 | CHRM4 (0.38) | CHRM4RETADAM17RPS6KB1CHRNA7 | |
| SCHEMBL8415324 | 0.79 | ADAM17 (0.47) | CHRM4ADAM17NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | CHRM4 4627/4885HPGDS 438/4885RET 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.